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Cross-sectional study of soluble selectins,
fractions of circulating microparticles and
their relationship to lung and skin
involvement in systemic sclerosis
Line V. Iversen1,2, Susanne Ullman1, Ole Østergaard2, Christoffer T. Nielsen2, Poul Halberg1, Tonny Karlsmark1,
Niels H.H. Heegaard2,3 and Søren Jacobsen4*
Abstract
Background: Endothelial damage and activation may play central roles in the pathogenesis of systemic sclerosis
(SSc) and are reflected by microparticles (MPs) and soluble selectins. The objective of this study was to determine if
these potential biomarkers are associated with specific organ involvements or cutaneous subgroups of SSc patients.
Method: MPs in platelet-poor plasma from 121 patients with SSc, 79 and 42 with limited and diffuse cutaneous
disease, respectively, were characterized by flow cytometry for their capacity to bind annexin V in combination with
surface markers of either platelets (PMPs), leukocytes (LMPs) or endothelial cells (EMPs). Soluble E- and P-selectin
levels were determined in plasma. By correlation analyses, this was held against involvement of skin, lung function,
lung fibrosis, pulmonary artery hypertension, and serology.
Results: None of the markers were associated with cutaneous subgroups of SSc. Concentrations of annexin V
non-binding EMPs and annexin V non-binding LMPs were negatively correlated to pulmonary diffusing capacity (DLCO)
(r = -0.28; p = 0.003; r = -0.26; p = 0.005) and forced vital capacity (FVC) (r = -0.24; p = 0.009; r = -0.29; p = 0.002), driven by
patients with limited and diffuse cutaneous disease, respectively. Soluble E-selectin levels correlated negatively to DLCO
(r = -0.21, p = 0.03) and FVC (r = -0.25; p = 0.007); and soluble P-selectin correlated negatively to DLCO (r = -0.23, p = 0.01).
Conclusion: Negative correlations between annexin V non-binding EMP and LMP concentrations with lung function
parameters (DLCO and FVC) differed between limited and diffuse cutaneous subsets of SSc, indicative of various
pathogeneses of lung involvement in SSc, possibly with a differential role of MPs.
Background
Systemic sclerosis (SSc; scleroderma) is a systemic auto-
immune connective tissue disease of unknown etiology,
characterized by vasculopathy and fibrotic changes in
the skin and various internal organs. Clinically, SSc is
classified according to the extent of skin involvement in
a limited cutaneous (lcSSc) and a diffuse cutaneous
(dcSSc) type, which may have different pathogenesis,
clinical courses and prognoses [1].
A major part of the increased mortality of patients with
SSc is due to lung involvement, i.e. interstitial lung fibrosis
and/or pulmonary arterial hypertension (PAH) [2]. Isolated
PAH is more common in lcSSc [3, 4] and lung fibrosis with
or without PAH is more frequent in dsSSc [5, 6]. Thus,
lung function tests showing an isolated reduction of the dif-
fusing capacity is most commonly seen in lcSSc while
restrictive lung disease is more typical of dcSSc [3, 4, 7].
These two patterns of abnormal lung function may repre-
sent different types of pathogenesis rather than different
stages of development.
Vasculopathy with perivascular inflammation and signs
of coagulation activation is an early and central event in
the pathogenesis of SSc [8]. Accordingly, several soluble
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markers of endothelial damage are increased in the cir-
culation of SSc patients such as soluble selectins, soluble
intercellular adhesion molecule 1, soluble vascular cell
adhesion molecule 1, thrombomodulin, von Willebrand
factor protein and endothelin-1 [8, 9]. Other markers of
endothelial damage may be subcellular particles, micro-
particles (MPs) [10] which are most often arbitrarily
defined according to size, 0.1-1.0 μm in diameter, but
may be even larger. Generation and shedding of MPs
occur during biological processes of considerable diversity,
including normal cellular differentiation, or apoptotic cell
breakdown, shear stress as present in arteries with severe
stenosis and during cellular activation following stimula-
tion with proinflammatory or prothrombotic substances
[11]. The membrane and membrane proteins of MPs
reflect their cellular origin allowing differentiation into e.g.
MPs derived from platelets (PMP), leukocytes (LMP), or
endothelial cells (EMP). The composition and content of
MPs likely reflect both the type and state of their parent
cells or tissues and make them potentially valuable markers
of inflammation or vascular reactivity.
The fraction of MPs, which does not bind annexin V,
AnxV non-binding MPs (AnxV− MPs), has been shown
increased in SSc patients, whereas concentrations of
AnxV positive MPs (AnxV+ MPs) did not differ from
healthy controls [12]. We therefore only correlated
AnxV− MP counts to disease manifestations and indica-
tors of disease activity in SSc and found AnxV− MPs
subsets to be associated with impaired lung function.
The AnxV− MPs most likely originate from activated
cells since their concentrations correlated with markers
of cellular activation (soluble E-selectin (sE-selectin,
sCD62E) and soluble P-selectin (sP-selectin, sCD62P))
in SSc [12]. Correlation of sE-selectin and sP-selectin
with lung function parameters in SSc patients may re-
flect activation of the lung endothelium in SSc lung
disease. The sE- and sP-selectins are released from acti-
vated platelets and endothelial cells, and as for the
AnxV− MPs, the contribution of selectins released in
excess from the lungs may contribute to the observed
correlation with lung function.
Methods
This cross-sectional study included 121 consecutive
patients fulfilling American College of Rheumatology
criteria [13] for SSc; 102 women and 19 men. Lung
fibrosis was not an inclusion criterion. Other aspects of
this patient population have been reported previously
[12]. All but one patient were Caucasians. Eight patients
received azathioprine, methotrexate, penicillamin, or
cyclosporine and 6 were given prednisolone at the time
of inclusion. None had received therapy with biological
drugs or prostanoid infusion within 6 month of inclu-
sion. Concomitant treatment of SSc patients included
among others calcium channel blockers, proton pump
inhibitors, angiotensin-converting enzyme inhibitors, di-
uretics, statins and non-steroidal anti-inflammatory
drugs. Patients with cancer, pregnancy or systemic infec-
tions were excluded. The study was approved by the
ethics committee of the capital region of Copenhagen
(approval number H-B-2008-131) and carried out in
accordance with the principles of the Declaration of
Helsinki. All participants were included after giving writ-
ten informed consent.
Clinical, biochemical and serological assessment
The clinical characteristics of the patients are summa-
rized in Table 1. Data on disease history including clin-
ical, serological and pharmacological data were obtained
by medical records, patient examination and interview.
Sub classification into limited and diffuse cutaneous dis-
ease was done according to LeRoy et al. [14].
Disease duration was defined as time since first non-
Raynaud SSc manifestation. All but one patient reported
the occurrence of Raynaud’s phenomenon after exposure
to low temperatures. At inclusion, the modified Rodnan
skin score was assessed in 17 body areas by the same ex-
perienced clinician [15]. Cutaneous ulcers were defined
as fingertip ulcers or other ulcers and registered as
present at enrollment or past ulcers. Subcutaneous calci-
nosis was demonstrated by X-ray of hands and/or feet
present at enrollment.
The lung function was determined within one year of
patient-inclusion by means of standard lung function
tests, including forced vital capacity (FVC) and diffusing
capacity of carbon monoxide (DLCO) measured by the
single-breath CO and helium CO-dilution technique stan-
dardized for hemoglobin level. FVC and DLCO were re-
ported in percent relative to predicted values with respect
to sex, age, height, and weight [16] and DLco- and FVC-
values lower than 80 % were considered pathological [17].
Isolated reduction of DLCO was defined as DLCO < 80 % of
the predicted value with FVC > 80 % of the predicted
value. Lung fibrosis was defined as radiographic signs of
lung fibrosis demonstrated by chest X-ray, which in 7
cases was supplemented with high resolution computed
tomography (HRCT).
Elevated systolic pulmonary arterial pressure measured
by echocardiography was defined as an estimated pressure
above 40 mmHg [18] and arterial hypertension was
defined as a blood pressure above 140/90 mmHg at study
inclusion.
Antinuclear antibodies (ANA) were detected by indir-
ect immunofluorescence technique on HEp-2 cells. Scl-
70-antibodies were demonstrated by ELISA. Routine
laboratory parameters were determined at the local
department of clinical biochemistry.
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Blood sampling and isolation of platelet-poor plasma
Venipuncture was performed with a 21-gauge needle, and
after release of the tourniquet the first tube was obtained
and always reserved for serological analyses. Next, for
microparticle isolation blood was collected into 3 x 9 mL
citrate tubes (Vacuette sodium citrate 3.8 %, Greiner Bio-
One, Kremsmünster, Austria) which were gently mixed 5
times. Immediately after collection, blood cells were re-
moved by centrifugation. The samples underwent a 2 step
centrifugation procedure: 1800 g, 10 min, 21 °C, followed
by a second centrifugation of the supernatant: 3000 g, 10
min, 21 °C, to obtain platelet poor plasma (PPP). The PPP
was aliquoted, snap-frozen in liquid nitrogen, and stored
at -80 °C until analysis [19, 20].
Analysis of MPs by flow cytometry
MPs, here defined as particles smaller than 1 μm, were
measured directly in platelet poor plasma [20]. In brief, a
panel of cell-specific monoclonal murine antibodies was
applied to label MPs originating from platelets (CD42a),
leukocytes (CD45) and endothelial cells (CD146). The
antibodies were used in the following formats and final
concentrations after titration experiments: anti-CD42a-
FITC (IgG1, 32 ng/mL, Becton-Dickinson, clone ALMA16),
CD45-PE (IgG1, 65 ng/mL, Becton-Dickinson, clone HI30)
and anti-CD146-FITC (IgG1, 262 ng/mL, AbD Serotec,
clone OJ79c). Labeling of MPs by specific antibodies was
compared to MPs labeled by isotype-matched control anti-
bodies (IgG1-FITC, Becton-Dickinson, clone MOPC-21;
Table 1 Demographical and clinical characteristics of 121 patients with systemic sclerosis
Patients All lcSSc dcSSc
Gender, males/females, n 19/102 3/76 16/26
Age, mean ± SD (range) years 57 ± 12 (22-79) 59 ± 11 55 ± 12
Disease duration, mean ± SD (range) years 12 ± 9 (0-53) 12 ± 9 11 ± 9
Cutaneous Involvement
Modified Rodnan skin score, mean ± SD 11 ± 9 7 ± 3 20 ± 9
Cutaneous ulcers, all, n 68 44 24
Cutaneous ulcers, present, n 23 10 13
Cutaneous ulcers, past, n 45 34 11
Calcinosis, n (N)* 43 (107) 30 13
Pulmonary and Cardiac involvement
DLCO, mean ± SD % predicted (N)* 64.6 ± 19.9 (118) 64.2 ± 18.5 (77) 66.3 ± 20.3 (41)
Patients with DLCO < 80 (%) 75 % 79 % 74 %
FVC, mean ± SD % predicted (N)* 95.7 ± 21.1 (118) 99.3 ± 20.1 (77) 89.1 ± 21.7 (41)**
Patients with FVC < 80 (%) 22 % 20 % 27 %
Radiographically confirmed lung fibrosis, n 21 14 7
Elevated SPAP by echocardiography, n (N)* 10 (115) 6 4
Serology
Anti-nuclear antibodies, n 116 74 42
Anti-Scl-70 antibodies, n 15 3 12
Anti-centromere antibodies, n 49 41 8
Peripheral blood
Leukocytes total, mean ± SD (x 109/L) 7.2 ± 2.2 7.4 ± 2.5 7.1 ± 2.3
Neutrophils, mean ± SD, (x 109/L) 4.6 ± 1.8 4.7 ± 2.0 4.4 ± 1.6
Platelets, mean ± SD, (x 109/L) 275 ± 86 265 ± 86 268 ± 72
Others
DMARDS, n 8 4 4
Current or previous smokers, n 83 57 26
Arterial hypertension, n 30 18 12
dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; anti-Scl-70: anti-topoisomerase-1; DMARDS: disease modifying anti
rheumatic drugs; arterial hypertension: blood pressure above 140/90 mmHg at study inclusion; DLCO: carbon monoxide diffusing capacity in percent of
predicted values; FVC: vital capacity in percent of predicted values. n: number of subjects with feature. N: total number of subjects in the group. *:
reduced number of patients due to lack of information. **, p < 0.01
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IgG1-PE Becton-Dickinson, clone MOPC-21) at the same
final concentration to set gate for positive events. AnxV-
binding to MPs was measured using AnxV-APC (10 ng/mL
final concentration, Becton-Dickinson) in the presence of 1
mM Ca2+. Platelet poor plasma aliquots (250 μL) were
thawed on melting ice. Labeling of MPs for flow cytomet-
ric analysis was carried out by mixing 5 μL prediluted
AnxV-APC and 5 μL prediluted specific antibodies or
isotype-matched control antibodies with 5 μL heparin-
sodium salt 10 % w/v (Sigma-Aldrich 194 USP/mg dry
basis. Heparin was added to avoid clotting of the plasma).
Finally, 5 μL PPP was added followed by dilution with 935
μL low phosphate buffered saline containing calcium,
(PBS-Ca; 154 mmol/L NaCl, 1.4 mmol/L phosphate, pH
7.4, 2.5 mM CaCl2) and incubation for 1 hour in the dark.
As a negative control experiment for AnxV binding, low
phosphate buffered saline containing citrate (PBS-citrate;
154 mmol/L NaCl, 1.4 mmol/L phosphate, pH 7.4, 10.5
mM trisodium citrate) was used for dilution replacing the
PBS-Ca.
To reduce background noise, buffers were filtered
through 0.1 μm pore size filters (MiniSart HF, Sartorius
Stedim Biotech S.A., Aubagne, France). Fresh buffers
were prepared on a weekly basis or more frequently if a
rise in background noise was observed indicating con-
tamination. The samples were analyzed using a FACS
Calibur flow cytometer (BD Biosciences) controlled by
CellQuest software version 5.1.1 in the “high” flow rate
mode. Flow rate was measured before each experiment.
Both forward scatter (FSC) and side scatter (SSC) were
recorded with logarithmic gain. Acquisition time was 60
seconds. MP gating was accomplished using 1 μm beads
(Flow Cytometry Size Calibration Kit, Molecular Probes,
Inc., Eugene, OR, USA) for setting upper limits in both
FSC and SSC signals, and a lower limit was placed to
exclude buffer noise. The MP gate was validated by
showing that the majority of AnxV+ MPs induced from
platelets using the calcium ionophore A23187 (Sigma,
Saint Louis, MO, USA) were detected using this gate
(data not shown). MPs gated this way were further
analyzed in SSC/FL-1, SSC/FL-2 or SSC/FL-4 plots to
discriminate labeled particles from unlabeled particles
using a fluorescence threshold determined by the fluor-
escence level of the MPs stained using the isotype-
matched control antibodies and AnxV non-binding
controls. Instrument settings were as previously described
[12]. Flow cytometric data analysis was performed using
FlowJo software version 7.6.1 (Tree Star, Inc., Ashland,
OR, USA).
MP-plasma concentrations of MPs were calculated as
MPs/mL based on MP count per unit time, flow rate of
the flow cytometer and net dilution during sample prepar-
ation of the analyzed sample. All samples were double-
labeled. The total cell derived population was calculated
as the sum of all the cell derived MP populations (EMPs,
LMPs and PMPs).
Selectins
Plasma concentrations of soluble E-selectin (sE-selectin,
sCD62E) and soluble P-selectin (sP-selectin, CD62P) were
measured using enzyme-linked immunosorbent assay kits
(Quantikine; R&D Systems; Minneapolis, MN). Serum
samples were diluted 1:10 for sE-selectin and 1:20 for sP-
selectin assays before analysis.
Statistical analysis
Pearson’s correlation analysis was used to examine rela-
tionships between MP concentrations, lung function
tests, and estimated pulmonary arterial pressure and
clinical blood samples. Data were logarithmically trans-
formed allowing parametric tests. In order to compare
MP concentrations between patients with and without
lung fibrosis Student’s t-tests were performed on loga-
rithmically transformed data. Student’s t-test was used
to compare the distribution of different clinical features
in the different SSc patient subsets. Statistical signifi-
cance was defined as p < 0.05. GraphPadPrism v. 5 and
Microsoft Excel 2010 were used for the statistical calcula-
tions and plots. Data on MP concentrations and soluble
selectin levels [12] are here correlated with clinical
parameters,
Results
We find no correlations between levels of MPs or
soluble selectins and modified Rodnan skin score in the
whole patient cohort or in subgroups. Also, no associa-
tions were found between MP concentrations and the
following variables: autoantibodies, pulmonary arterial
hypertension (PAH), digital ulcers neither present at
enrolment nor only in the past, disease duration, smok-
ing status, age, hypertension, IgM rheumatoid factor, C-
reactive protein, or use of the following medications: low
dose aspirin, calcium channel blockers and/or statins.
SSc patients with calcinosis had a significantly lower
concentration of AnxV− EMPs (p = 0.04, Table 3).
Lung function and circulating E- and P-selectins
Soluble E- and P-selectins are markers for damaged and/
or activated endothelium and platelets and have previ-
ously been shown to be elevated in SSc patients com-
pared to healthy controls, nevertheless no objective
measures of lung function were reported in these studies
[12, 21–24]. Here data on lung function (vital and diffus-
ing capacity) were available for 118 patients (Table 1).
While diffusing capacity (DLCO) did not differ between
the lcSSc (n = 77) and the dcSSc (n = 41) subgroups,
there was a highly significant (p < 0.01) decreased vital
capacity (FVC) in the dcSSc group (Table 1). Other
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studies have shown both equal and lower FVC and
DLCO in dcSSc compared with lcSSc patients [25, 26]. In
our cohort, the DLCO was reduced in both patient sub-
groups (average of all 118 patients was 65 % ± 20 % (1
SD)) and FVC was lower in the dcSSc group (99 % vs.
89 %) compared with the lcSSc group. Soluble E-selectin
correlated inversely with measures of lung function, both
with FVC and DLCO (r = -0.25; p = 0.007 and r = -0.21; p
= 0.03, respectively) (Fig. 1) and soluble P-selectin corre-
lated with DLCO (r = -0.23; p = 0.012). Thus, higher levels
of these circulating selectins were found in patients with
decreased lung function irrespectively of lcSSc or dcSSC
status. As expected [27], soluble P-selectin correlated
with platelet counts (r = 0.34, p = 0.001) but also with
the neutrophil count (r = 0.27; p = 0.003). Also, soluble
E-selectin was significantly increased (p = 0.006) in the
21 patients with chest x-ray confirmed lung fibrosis.
Lung function and circulating microparticles
Circulating microparticles (MPs) were enumerated
and phenotyped using flow cytometry on platelet-poor
plasma samples from all 121 patients. MPs were
probed for Annexin V binding, and for the expression
of endothelial (CD146), leukocyte (CD45), and platelet
(CD42a) markers. AnxV− MPs were inversely correlated
to lung function parameters for MPs derived from endo-
thelial cells and leukocytes but not for platelet-derived
MPs (Fig. 2) (DLCO, r = -0.28; p = 0.003, and r = -0.26; p =
0.005, respectively; FVC, r = -0.24; p = 0.009, and r = -0.29;
p = 0.002, respectively). The correlation with FVC was
driven by the dcSSc subgroup where the correlation was
highly significant (p < 0.01). The correlation with DLCO
appeared to be driven by the lcSSc subgroup while the
DLCO and AnxV
− MPs were not significantly correlated in
the dcSSc subgroup (Table 2). Both AnxV− EMPs and
AnxV− LMPs correlated with neutrophil counts (r = 0.30;
p = 0.001 and r = 0.24; p = 0.008, respectively). For the 21
cases with chest x-ray confirmed lung fibrosis we found
an average of 94 % increased concentration of AnxV−
EMPs compared to cases without fibrosis (p = 0.02,
Table 3). This association was driven by the 7 patients in
the dcSSc group (p = 0.02 compared with dcSSc patients
without lung fibrosis (n = 35)) as MP levels did not differ
in the lcSSc patients with and without lung fibrosis.
Fig. 1 Plasma levels of soluble E- and P-selectins correlate with lung function parameters in systemic sclerosis patients. Soluble E-selectin (log ng/
mL) correlated with (a) carbon monoxide diffusing capacity in percent of predicted values (DLCO %) (r = -0.21; p = 0.03) and (b) forced vital
capacity in percent of predicted values (FVC %) (r = -0.25; p = 0.007). P-selectin (log ng/mL) correlated with (c) DLCO % (r = -0.23; p = 0.01) but
not with (d) FVC %. Correlation analysis was performed by use of Pearson’s r test using log transformed selectin-levels
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Discussion
In this study, we found the concentration of AnxV−
EMPs and AnxV− LMPs to be inversely correlated with
the lung function in SSc patients as measured by DLCO
and FVC. These correlations were dissimilar in patients
with limited and diffuse disease. Even though the extent
of cutaneous and pulmonary involvement in SSc are not
directly correlated [5, 6] this difference may reflect an
increased prevalence of restrictive lung disease in pa-
tients with dcSSc and increased prevalence of isolated
pulmonary hypertension more often is seen in lcSSc [3].
The dissimilar correlation between MP counts in pa-
tients with dcSSc and lcSSc to FVC and Dlco, respect-
ively, may also support the notion that different types of
Fig. 2 Plasma levels of annexin V non-binding, cell-derived microparticles (AnxV− MPs) correlated to lung function parameters. Endothelial cell
derived MPs and leukocyte derived MPs (log counts/mL) correlated with both carbon monoxide diffusing capacity in percent of predicted
values (DLco, %) (r = -0.28; p = 0.003, and r = -0.26; p = 0.005) respectively (a and b) and forced vital capacity in percent of predicted values
(FVC, %) (r = -0.24; p = 0.009, and r = -0.29; p = 0.002) respectively (c and d). No correlations between AnxV− platelet derived MPs and lung
function parameters were found (e and f). Correlation analysis was performed by use of Pearson’s r test using log transformed
microparticle data
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lung involvement exists in these two subsets of patients
possibly related to different activation of coagulation and
fibrinolysis. For instance, dermatan sulfate, which coats
endothelial cells and modulates their adhesiveness and
immunogenicity was only found increased in plasma
from dcSSc and plasminogen activation inhibitor (PAI)
was only elevated in lcSSc [21]. The associations be-
tween lung function and levels of AnxV− EMPs and
AnxV− LMPs may reflect an increased activation of
endothelial cells and leukocytes in the lungs. It has been
shown that pulmonary microvascular endothelial cells
and aortic endothelial cells in vitro generate diverse
numbers and subtypes of EMPs in response to different
proinflammatory stimuli [28]. Accordingly, the use of
other endothelial cell markers than CD146 would be of
interest to explore in future studies. Furthermore,
HRCT, today mandatory in the diagnosis of ILD in SSc
patients, would be beneficial to elaborate the connection
between MPs, lung function test and lung fibrosis, as
this examination is a more sensitive detector of the
extent and severity of interstitial lung involvement [29].
Only few previous studies report on circulating AnxV−
MPs [12, 19, 30] and only one has characterized these
MPs in SSc patients and found that the fraction of AnxV
− MPs was higher than in healthy controls [12]. Three
groups have reported that circulating overall MP con-
centrations in SSc patients are equal or elevated com-
pared with healthy controls [23, 31, 32]. One study
found elevated numbers of PMPs in SSc-interstitial
pneumonitis, but had no information about lung func-
tion or radiographic findings [23]. Another study found
elevated PMP concentrations in SSc patients with PAH
defined as values above 25 mmHg estimated by echocar-
diography. The PMP levels in these patients were also
found to correlate with the increased pulmonary arterial
pressures [31]. We do not reproduce these findings. We
find no overall increased MP-concentrations and no
MP-correlations to pulmonary arterial pressure (using
an echo-pressure threshold of 40 mmHg). Right heart
catheterization is however a more accurate method to
asses PAH than transthoracic echocardiography, but the
risk and discomfort associated with this test made it un-
acceptable to use in this study [33].
Other clinical connections reported are inverse correl-
ation of total MPs and PMPs to modified Rodnan skin
score, and lower total numbers of MPs and PMPs in
patients with digital ulcers [31]. We could not confirm
this. Only one other study reports a link between re-
duced lung function and EMPs which was found in
healthy smokers compared to healthy controls. In this
study, a reduced DLCO was found to be inversely corre-
lated with the concentration of EMPs in smokers [34].The
reasons for these discrepancies are unknown but may be
Table 2 Correlation of annexin V non-binding (AnxV−) MP levels
to lung function parameters in patients with systemic sclerosis
Lung function
DLco FVC
dcSSc lcSSc dcSSc lcSSc
(n =41) (n = 77) (n =41) (n = 77)
r R r R
log(AnxV− EMPs) −0.21 −0.32** −0.43** −0.15
log(AnxV− LMPs) −0.22 −0.28* −0.42** −0.19
log(AnxV− PMPs) −0.06 −0.08 −0.18 −0.03
dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic
sclerosis. DLCO: Diffusing capacity for carbon monoxide. FVC: Forced vital
capacity. Pearson’s r on log transformed data. P < 0.05*. P < 0.01**
Table 3 Concentrations of annexin V non-binding (AnxV−) MP subsets stratified by the presence of selected disease manifestation
of systemic sclerosis (SSc)
Clinical Variable AnxV− EMPs AnxV− LMPs AnxV− PMPs
(MP x 105) (MP x 104) (MP x 105)
Symptom No symptom P Symptom No symptom p Symptom No symptom p
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Skin
Cutaneous ulcer 8.01 ±6.83 11.48 ±16.11 0.64 9.47 ±8.80 5.73 ±31.49 0.84 4.59 ±3.92 5.79 ±7.88 0.66
Calcinosis 10.75 ±9.71 9.16 ±13.68 0.04 14.04 ±18.78 14.59 ±33.08 0.07 6.87 ±10.39 4.41 ±4.46 0.17
Heart
SPAP > 40 18.46 ±28.31 10.13 ±13.10 0.63 24.64 ±37.96 14.29 ±27.95 0.96 4.63 ±4.84 5.64 ±7.54 0.43
Lung
Fibrosis (among all) 18.06 ±22.91 9.30 ±12.26 0.02 23.67 ±35.67 13.35 ±27.08 0.14 5.29 ±4.82 5.62 ±7.79 0.83
Fibrosis (among dcSSc) 22.13 ±28.29 9.43 ±12.36 0.02 28.14 ±39.47 13.46 ±27.34 0.13 7.19 ±6.97 5.49 ±7.80 0.54
Fibrosis (among lcSSc) 16.03 ±20.61 9.43 ±12.36 0.12 21.44 ±34.96 13.46 ±27.34 0.40 4.34 ±3.23 5.49 ±7.80 0.87
Student's t test: significance level: p < 0.05 in bold
mRSS: modified Rodnan skin score. SPAP: Systolic pulmonary arterial pressure. dcSSc; diffuse cutaneous SSc. lcSSc: limited cutaneous SSc
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related to technical, physiological, and sample size param-
eters. Also, the size and the composition of the circulating
MP population depend on several physiological variables
including exercise, menstrual cycle, age, body mass index,
and on countless pathologic conditions as well as on
smoking and the intake of medicine. Consequently, it is
necessary to study large numbers of patients to minimize
the impact of biological/physiological variation that may
interfere with the study results [35]. As to the selection of
patients for this study, the mean disease duration of the
patients was 12 years and only 3 patients did not have
proximal cutaneous sclerosis, which indicated that the pa-
tients in this study were well into the disease process.
Using the new 2013 ACR/EULAR criteria for SSc might
have resulted in the inclusion of more patients with
discreet symptoms or early SSc, which could have had
implications for the results obtained. However, this
study was performed before prior to the launching of
these criteria [36, 37].
The concentration of AnxV− MPs in fresh (never fro-
zen), samples is likely to be higher than when using frozen
plasma samples as freezing has been shown to induce in-
crease phosphatidylserine exposure and thereby to in-
crease binding of annexin V to all MPs [20, 38]. MPs that
do not expose PS after freezing may well have specific
characteristics which remain to be elucidated, as should
more detailed studies of differences between fresh and fro-
zen samples.
Conclusions
In this study of a large number of clinically well-
characterized SSc patients that were sampled under con-
trolled and identical conditions, we find that levels of cir-
culating AnxV− EMPs and AnxV− LMPs are inversely
correlated with the lung function as measured by DLCO
and FVC. Worse lung function correlates with higher
levels of Anx V non-binding MPs. These correlations are
different in patients with limited and diffuse disease. In
dcSSc the increased concentration of AnxV− MPs from
endothelial cells and leucocytes is related to a reduction of
FVC, whereas in lcSSc the same MP compartment is asso-
ciated with a reduction of DLCO. The observation that the
concentration of AnxV− EMPs was higher in patients with
chest x-ray confirmed lung fibrosis merits further studies
supported by HRCT and including longitudinal studies
with consecutive sampling. Also, further characterization
of the composition and origin of the unique MP popula-
tions, especially the MPs that do not bind annexin V, that
circulate in SSc patients is required to increase our under-
standing of the putative role of MPs in the pathogenesis
and disease activity monitoring in SSc.
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